Synthego Stock
Genome Engineering Solutions
Sign up today and learn more about Synthego Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synthego Stock
Synthego is a provider of genome engineering solutions. The company offers CRISPR kits, such as the CRISPR evolution, a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego claims that its CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Select applications of gene editing include pathway analysis, stem cells, and diagnostics. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells.
The company is headquartered in Redwood City, CA, and was founded in July 2012. Notable investors include Founders Fund, 8VC, and Menlo Ventures.
Investors
Menlo Ventures
Uber, Chime, Machine Zone, Getaround, BitSight, Recursion Pharmaceuticals, Outreach, Harness, Benchling, Synthego
Founders Fund
Lyft, Spotify, Airbnb, Stripe, Flexport, Palantir Technologies, Wish, Compass, Zenefits, Eat Just
8VC
Anduril Industries, Sila Nanotechnologies, Cityblock Health, project44, Blend, Aspiration, Addepar, Illumio, BlueVoyant, Guardant Health
Alexandria Venture
ZhenFund
Bolt Financial, Synthego, The Minerva Project, Artsy, Osaro, Stratifyd
Funding History
June 2013 | $8.3M |
---|---|
December 2016 | $4.4M |
December 2016 | $41.9M |
October 2018 | $116M |
June 2020 | $100M |
December 2021 | $144M |
Management
Chief Executive Officer
Paul Dabrowski
Chief Financial Officer
Avi Raval
Press
prnewswire - Feb, 4 2024
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developersrwcpulse - Dec, 22 2023
Synthego opens new biotech life science research lab in ...genengnews - Dec, 22 2023
Shuttle Launch: Cellares' Smart Factories Aim to Meet Cell ...genengnews - Dec, 22 2023
Amped Up: VedaBio Launches with $40+ Million Toward a ...prnewswire - Oct, 4 2023
Synthego Bridges Critical Preclinical Gap to Accelerate CRISPR-based Cell and Gene Therapies